Literature DB >> 35176918

Procedural outcomes associated with use of the AngioVac System for right heart thrombi: A safety report from RAPID registry data.

John M Moriarty1, Millie Liao2, Grace Hyun J Kim3,4, Eric Yang4, Kush Desai5, Mona Ranade1, Adam N Plotnik1.   

Abstract

Background: Right heart thrombi can be a source of considerable morbidity and mortality, especially when associated with pulmonary embolism.
Methods: To understand the safety and procedural efficacy associated with vacuum-assisted thrombectomy using the AngioVac System (AngioDynamics, Latham, NY, USA) to remove right heart thrombi, we conducted a subanalysis of the Registry of AngioVac Procedures in Detail (RAPID) multicenter registry representing 47 (20.1%) of 234 participants in the registry. Forty-two (89.4%) patients had thrombi located in the right atrium alone, three (6.4%) in the right ventricle alone, and two (4.3%) in both the right atrium and ventricle. Four (8.5%) patients had concomitant caval thrombi, three (6.4%) also had catheter-related thrombi, and one (2.1%) patient had both caval and catheter-related thrombi with their right heart thrombi.
Results: Extracorporeal bypass time was less than 1 hour for 39 (83.0%) procedures. Seventy to 100% removal of thrombus was achieved in 59.6% of patients. Estimated blood loss was less than 250 cc for 43 procedures (91.6%). Mean hemoglobin decreased from 10.7 ± 2.2 g/dL preoperatively to 9.6 ± 1.6 g/dL postoperatively. Transfusions were administered for eight procedures (17.0%), with only one (2.1%) patient receiving more than 2 units of blood. Six patients (12.8%) experienced procedure-related adverse events, including three (6.4%) patients who experienced distal emboli and three (6.4%) patients who developed bleeding-related complications. All adverse events resolved prior to discharge. There was one death (2.1%) reported that was not procedure related.
Conclusion: Vacuum-assisted thrombectomy can be performed safely in patients with right heart thrombi. ClinicalTrials.gov Identifier: NCT04414332.

Entities:  

Keywords:  Clot in transit (CIT); endovascular therapy; pulmonary embolism (PE); venous thromboembolism (VTE)

Mesh:

Year:  2022        PMID: 35176918     DOI: 10.1177/1358863X211073974

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  1 in total

1.  Clot In Transit in a Patient with Protein S Deficiency.

Authors:  Simon Kashfi; Mohamed Farhan Nasser; Aron Soleiman; Sapna Sharma; Venkata Sandeep Koripalli; Shorabh Sharma
Journal:  Eur J Case Rep Intern Med       Date:  2022-05-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.